the efficacy of nintedanib for expression of surfactant protein

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K09619
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Sapporo Medical University
• Principal Investigator: Otsuka Mitsuo 札幌医科大学, 医学部, 研究員 (10398323)
• Co-Investigator(Kenkyū-buntansha): 高橋 弘毅 札幌医科大学, 医学部, 教授 (60231396)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 特発性肺線維症 / SP-A / 抗線維化薬

Outline of Final Research Achievements

Background: We aim to clarify whether serum SP-A, SP-D, and KL-6 reflect therapeutic outcomes of pirfenidone and nintedanib administration in patients with IPF. Methods: We retrospectively investigated patients with IPF who were initiated on pirfenidone or nintedanib administration between January 2014 and June 2018 at our hospital. Changes in clinical parameters and serum SP-A, SP-D, and KL-6 levels were evaluated. Results: Forty-nine patients were included (pirfenidone, 23; nintedanib, 26). Stable group comprised 32 patients, while progression group comprised 17 patients. In the stable group, changes in SP-A and KL-6 from baseline to 3 and 6 months significantly decreased compared with the progression group. Changes in SP-A and SP-D levels showed significant negative correlations with the change in %FVC and %DLco. Conclusions: Serum SP-A has a potential as a biomarker of therapeutic outcomes of anti-fibrotic drugs.

Free Research Field

呼吸器病学

Academic Significance and Societal Importance of the Research Achievements

本研究により、間質性肺炎の血清バイオマーカーであるSP-Aが、抗線維化薬の効果予測バイオマーカーになりうることが明らかとなった。実臨床で測定可能であるので臨床応用可能である。